Los Angeles Capital Management LLC Buys 40,383 Shares of Alumis Inc. $ALMS

Los Angeles Capital Management LLC increased its stake in Alumis Inc. (NASDAQ:ALMS) by 32.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 163,084 shares of the company’s stock after acquiring an additional 40,383 shares during the period. Los Angeles Capital Management LLC’s holdings in Alumis were worth $1,592,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Samsara Biocapital LLC increased its stake in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the period. Vanguard Group Inc. raised its position in shares of Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after acquiring an additional 625,404 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Alumis during the second quarter valued at $5,779,000. Woodline Partners LP boosted its holdings in Alumis by 809.7% in the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after acquiring an additional 1,558,660 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Alumis by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 1,487,626 shares of the company’s stock valued at $14,523,000 after acquiring an additional 94,340 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. HC Wainwright cut Alumis from a “buy” rating to a “neutral” rating and set a $25.00 price objective for the company. in a report on Friday, May 15th. Raymond James Financial assumed coverage on shares of Alumis in a research note on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 target price on the stock. Oppenheimer lifted their price target on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Stifel Nicolaus began coverage on shares of Alumis in a research note on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target for the company. Finally, Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Up 0.2%

Shares of Alumis stock opened at $20.06 on Thursday. The business has a fifty day simple moving average of $22.84 and a 200 day simple moving average of $21.07. The stock has a market cap of $2.56 billion, a PE ratio of -10.13 and a beta of -0.56. Alumis Inc. has a 12 month low of $2.76 and a 12 month high of $30.60.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. Analysts expect that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.